Thursday, November 21, 2019 8:48:37 AM
Download as PDFNOVEMBER 21, 2019 8:00AM EST
HOUSTON, Nov. 21, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, filed a Pre-IND meeting request for Berubicin for IV for the Treatment of Glioblastoma Multiforme to the US Food and Drug Administration Division of Oncology Products 2, Center for Drug Evaluation and Research.
In its request, the Company outlined its rationale for the continued investigation of the compound and detailed key questions for the FDA, including its permission to utilize the supply of Berubicin acquired from Reata Pharmaceuticals Inc. in the planned upcoming Phase II clinical trial. The company has performed a preliminary purity testing and analysis on Reata's supply of Berubicin and verified that it is 99.9% pure.
"We believe that utilizing the supply of Berubicin we acquired from Reata could offer the Company significant costs savings and eliminate the excess risk and time associated with manufacturing complex drugs," stated CEO of CNS, John M. Climaco.
Recent CNSP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 08:30:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 12:58:31 PM
- IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc. • GlobeNewswire Inc. • 09/03/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:22:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:30:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 09:11:50 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 08:53:41 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 08/02/2024 08:11:48 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 07/31/2024 04:32:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/30/2024 09:15:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:13:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 11:00:51 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 12:30:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 12:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 01:30:08 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/19/2024 09:12:54 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/12/2024 08:30:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 03:25:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/17/2024 03:17:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:25:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 09:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 02:56:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:00:33 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM